Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
Audax Biosciences runs a Biotechnology Research operation from Melbourne, VIC. It is privately held, and its site is audax.bio. It holds one address on record, all in Australia. Headcount on record is 22. Its work is tagged pharma, cancer and biotech. One Australian registration (ABN) is a confirmed match. The record links ten similar brands, most of them in Biotechnology Research.
ABN26625632564
| AUDAX BIOSCIENCES PTY. LTD. | ABN 26625632564 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
A unique Australian biotechnology company inventing targeted immunotherapies for oncology and autoimmune diseases.
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
One Victoria entity on the ABR: AUDAX BIOSCIENCES PTY. LTD. (ABN 26 625 632 564), high confidence.
22 counted staff profiles at January 2026, inside the self-reported 11–50 band.
One address on record, Australia only. Primary: Melbourne, VIC 3000.
None linked to this brand.
Seven tags on the brand's own list, among them pharma, cancer and biotech.
13 profiles list Audax Biosciences as a peer — 87th percentile in Biotechnology Research. It lists ten peers of its own. Prescient Therapeutics and Exopharm Ltd list it back.